GlassScriptPhysician profile
James B Connors
NPI 1548255250
$14,596.34
in general payments reported to CMS, 2019-2025
27 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 76% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,392 · 2020: $452 · 2021: $669 · 2022: $922 · 2023: $855 · 2024: $1,180 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,161.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $9,039.73 | 2019-2023 | Erivedge |
| Novartis Pharmaceuticals Corporation | $1,024.21 | 2019-2025 | |
| Abbvie INC. | $747.38 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Sun Pharmaceutical Industries INC. | $688.13 | 2019-2025 | Odomzo, Ilumya, Blu-U |
| Amgen INC. | $583.61 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $450.21 | 2021-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $442.46 | 2019-2025 | |
| Janssen Biotech, INC. | $221.97 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $201.00 | 2022-2025 | Taltz, Ebglyss, Zepbound |
| Organogenesis INC. | $172.78 | 2022-2025 | Puraply, Puraply Wound Matrix |
| Leo Pharma INC. | $145.64 | 2019-2020 | |
| Celgene Corporation | $132.43 | 2019 | |
| Almirall LLC | $128.31 | 2021-2025 | Seysara, Klisyri |
| Kerecis Limited | $118.09 | 2022-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.05 | 2023-2025 | Spevigo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $80.35 | 2019-2020 | |
| Pfizer INC. | $78.28 | 2019-2022 | |
| Incyte Corporation | $50.25 | 2022-2023 | Opzelura |
| Galderma Laboratories, L.P. | $30.42 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.15 | 2025 | Sotyktu |
| Dermavant Sciences, INC. | $21.32 | 2022 | |
| Dusa Pharmaceuticals, INC. | $20.92 | 2019 | |
| Krystal Biotech INC | $20.27 | 2025 | Vyjuvek |
| Paratek Pharmaceuticals, INC. | $19.21 | 2024 | Nuzyra |
| Mayne Pharma Commercial LLC | $18.10 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.89 | 2024 | Zoryve |
| Dermira, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Connors listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.